Kolexia
Torossian Nouritza Oncologie hémato.
Torossian Nouritza
Oncologie hémato.
Centre Hospitalier Régional D'Orléans Hôpital de La Source
Orléans, France
61 Activités
1.7 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinome épidermoïde Carcinomes Mélanome Carcinome épidermoïde de la tête et du cou Métastase tumorale Tumeurs du foie Tumeurs du sein Seconde tumeur primitive {{person.topmesh10.name}}

Collaborateurs

Voir plus
Doucet Ludovic
Doucet Ludovic
Institut de cancérologie de l'Ouest, Saint-Herblain, France
Gauthier Helene
Gauthier Helene
Hôpital Saint-Louis, Paris, France
Borcoman Edith
Borcoman Edith
Clcc Institut Curie, Paris, France
Defaucheux Cecile
Defaucheux Cecile
Centre Hospitalier d'Arcachon, La Teste-de-Buch, France

Industries

Voir plus
Janssen
1 collaboration(s)
Dernière en 2021
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases.
British journal of cancer   13 juillet 2023
Nouvelles immunothérapies ciblant les points de contrôle immunitaire : les agonistes d’OX40 et les inhibiteurs de LAG-3
Edimark   31 mai 2023
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy.
Drugs in R&D   25 septembre 2021
Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck.
European journal of cancer (Oxford, England : 1990)   15 septembre 2021
Advances in theranostic biomarkers for tumor immunotherapy.
Current opinion in chemical biology   24 mars 2020
Clinical Development of Molecular Targeted Therapy in Head and Neck Squamous Cell Carcinoma.
JNCI cancer spectrum   12 novembre 2019
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
European journal of cancer (Oxford, England : 1990)   05 octobre 2019
First-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September – 1 October 2019, Barcelona, Spain   01 octobre 2019
Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September – 1 October 2019, Barcelona, Spain   01 octobre 2019